The volume of pharma and biotech deals fell in the first quarter year-over-year, but values spiked 141% from the fourth quarter, driven by high-value deals, according to the quarterly Global Pharma & Life Sciences Deals Insights from PricewaterhouseCoopers.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,